Answers are grounded in this paper and cite their sources.
Antimicrobial resistance (AMR) in Gram-negative bacteria is frequently mediated by multiple resistance determinants within the same isolate. Their co-occurrence patterns and relationship with antimicrobial susceptibility remain incompletely characterized in Southeast Asia. To describe major resistance-gene distributions, evaluate pairwise gene associations, examine species-specific patterns, and characterize selected antimicrobial susceptibility profiles among multidrug-resistant (MDR) Gram-negative bacteria. This retrospective cross-sectional laboratory-based study included 313 non-duplicate MDR Gram-negative isolates collected at Da Nang Hospital, Central Vietnam, from December 2024 to February 2026. Gene positivity was calculated among isolates tested for each determinant. Pairwise associations were evaluated using Fisher’s exact test and odds ratios (ORs), with Benjamini–Hochberg false discovery rate (FDR) correction. Klebsiella pneumoniae was analyzed separately. Species-adjusted analysis was also performed. Genotype–phenotype comparisons were summarized descriptively because of sparse subgroup sizes. K. pneumoniae was the predominant species (171/313, 54.6%). Among tested isolates, blaNDM , blaOXA-48-like , blaCTX-M , and blaTEM were detected in 66.2%, 52.0%, 83.5%, and 66.9%, respectively. After FDR correction, blaKPC–blaNDM , blaNDM–blaOXA-48-like , and blaNDM–blaCTX-M showed inverse associations, whereas blaOXA-48-like–blaCTX-M showed a positive association. In K. pneumoniae , blaKPC remained inversely associated with blaNDM and blaOXA-48-like . The species-adjusted association between blaNDM and blaOXA-48-like was not statistically significant. Among 101 Enterobacterales isolates with complete molecular and phenotype data, aztreonam plus ceftazidime/avibactam showed 95.6% susceptibility (87/91) in the carbapenemase-plus- blaCTX-M / blaTEM group. Resistance genes showed heterogeneous pairwise associations that should be interpreted in the context of species composition and non-uniform testing. High in vitro susceptibility to aztreonam plus ceftazidime/avibactam was observed in the tested subset, but these findings should be interpreted as descriptive laboratory data rather than evidence of clinical effectiveness.
No takes yet. Share an insight, caveat, or question.
Le et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: